WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2018--
Inc. (Nasdaq: IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that the underwriters of its previously announced public
offering of common stock have exercised in full their option to purchase
an additional 2,055,000 shares of ImmunoGen’s common stock at a price of
$11.00 per share, before underwriting discounts. The exercise of the
option brings the total shares of common stock to be sold by ImmunoGen
in the offering to 15,755,000 shares. All of the shares in the offering
are to be sold by ImmunoGen. The offering of the option shares is
expected to close on or about June 25, 2018, subject to satisfaction of
customary closing conditions.
ImmunoGen anticipates the gross proceeds from the offering of the option
shares will be approximately $22.6 million, bringing the anticipated
total gross proceeds to ImmunoGen from the offering (before deducting
the underwriting discounts and offering expenses) to approximately
$173.3 million. ImmunoGen anticipates using the net proceeds of the
offering, together with its existing capital, to fund its operations,
including, but not limited to, research and development activities,
clinical trial activities, manufacturing and supply of drug substance
and drug products, commercialization preparation, acquisitions of new
technologies, capital expenditures and working capital.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and
Company, LLC acted as joint book-running managers for the offering.
Canaccord Genuity LLC acted as lead manager and H.C. Wainwright & Co.
acted as co-manager for the offering.
The securities described above were offered by ImmunoGen pursuant to a
shelf registration statement that was previously filed with the
Securities and Exchange Commission (SEC) and became effective upon
filing. This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in this offering, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
any such state or other jurisdiction. A prospectus supplement and
accompanying prospectus relating to the offering was filed with the SEC
and is available on the SEC’s website at www.sec.gov.
Copies of the prospectus supplement and accompanying prospectus may be
obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (866) 803-9204, or by email at firstname.lastname@example.org;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or by
email at email@example.com;
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or
by calling (631) 274-2806.
ImmunoGen is developing the next generation of antibody-drug conjugates
(ADCs) to improve outcomes for cancer patients. By generating targeted
therapies with enhanced anti-tumor activity and favorable tolerability
profiles, we aim to disrupt the progression of cancer and offer our
patients more good days. We call this our commitment to “target a better
now.” Our lead product candidate, mirvetuximab soravtansine, is in Phase
3 study for folate receptor alpha (FRα)-positive platinum-resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our
novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632,
are in Phase 1 studies.
This press release includes forward-looking statements, including
statements related to the public offering of securities by ImmunoGen,
including statements about the completion and timing of the offering of
the option shares, the expected gross proceeds from the offering and the
anticipated use of the net proceeds of the offering. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. Various factors could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date of
this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to,
uncertainties inherent in the initiation of future clinical trials and
such other factors more fully described in ImmunoGen’s Annual Report on
Form 10-K for the year ended December 31, 2017 and other reports filed
with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005599/en/
Source: ImmunoGen, Inc.
INVESTOR RELATIONS CONTACT
Courtney O’Konek, 781-895-0600
Robert Stanislaro, 212-850-5657